Kailera Therapeutics, Inc.
KLRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002096997
No open-market purchases or sales by Kailera Therapeutics, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $2.58B in total; Soros Fund Management is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +100 vs. previous quarter
- 100
- 13F valueReported value at the end of Q2 2026
- $2.58B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding KLRA, Q2 2026
1 superinvestor reports holding Kailera Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
<0.1%
Kailera Therapeutics, Inc.'s share of the portfolio
- Shares
- 20,000
- Value
- $440.6K
Latest insider trades
Open-market purchases and sales by Kailera Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 22, 2026 (view filing)4:15 PM ET | Apr 20 | 2 days | RTW Investments, LP and 1 other10% Owner | PPurchase | +500.0K | $16.00 | +$8.00M | +4.9%10.8M after | |
| Apr 20, 2026 (view filing)6:10 PM ET | Apr 20 | Same day | Bain Capital Investors LLC and 4 others10% Owner | PPurchase | +8.40M | $16.00 | +$134.4M | +47.0%26.3M after | Duplicate filing |
| Apr 20, 2026 (view filing)6:01 PM ET | Apr 20 | Same day | Bain Capital Life Sciences Investors, LLC and 4 others10% Owner | PPurchase | +1.56M | $16.00 | +$25.0M | +7.4%22.6M after | Duplicate filing |
| Apr 20, 2026 (view filing) | Apr 20 | Same day | Koppel AdamDirector, 10% Owner | PPurchase | +1.56M | $16.00 | +$25.0M | +7.4%22.6M after | |
| Apr 20, 2026 (view filing) | Apr 20 | Same day | Kaplan Andrew T.Director, 10% Owner | PPurchase | +8.40M | $16.00 | +$134.4M | +47.0%26.3M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Kailera Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bain Capital Investors LLC | 26,255,581 | $578.4M | 12.01% | +26,255,581 | New |
| Bain Capital Life Sciences Investors, LLC | 22,583,268 | $497.5M | 29.58% | +22,583,268 | New |
| RTW Investments, LP | 10,776,820 | $237.4M | 2.03% | +10,776,820 | New |
| Canada Pension Plan Investment Board | 7,304,688 | $160.9M | 0.09% | +7,304,688 | New |
| Atlas Venture Life Science Advisors, LLC | 5,171,282 | $113.9M | 12.93% | +5,171,282 | New |
| FMR LLC | 3,970,865 | $87.5M | 0.00% | +3,970,865 | New |
| BlackRock, Inc. | 3,928,604 | $86.5M | 0.00% | +3,928,604 | New |
| Price T Rowe Associates Inc | 3,534,410 | $77.9M | 0.01% | +3,534,410 | New |
| Citadel Advisors LLC | 3,240,787 | $71.4M | 0.04% | +3,240,787 | New |
| Adage Capital Partners GP, L.L.C. | 3,208,286 | $70.7M | 0.10% | +3,208,286 | New |